Penrose, through unprecedented tissue-driven pharmacologic insights, has pioneered a next-generation class of Mitochondrial Modifying Agents (MMA), which create a selective mitochondrial vulnerability that ultimately lead to cancer cell metabolic collapse. Since mitochondria are essential bioenergetic, biosynthetic, and signaling factories that are critical for cancer cell survival and growth, we’re going straight to the epicenter of cancer cell survival, killing them from the inside out.
Small molecules reprogram cancer cell mitochondria to a point of therapeutic vulnerability to metabolic collapse
Heavily pretreated, relapsed/refractory cancers are more vulnerable to the MMA approach, allowing use of low doses of therapeutics with potential for an extremely wide therapeutic window
In addition to our lead candidate, Penrose has identified additional assets that are hypothesized to be more effective based on our rational chemistry-driven foundation. These include RP-0330 and RP0340. The Penrose scientific teams are utilizing high throughput screening to evaluate these compounds in early preclinical research, as well as identify additional analogues for testing.